Connor, Clark & Lunn Investment Management Ltd. Xeris Biopharma Holdings, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $28.9 Billion
- Q3 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 1,698,757 shares of XERS stock, worth $12.3 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
1,698,757
Previous 1,227,959
38.34%
Holding current value
$12.3 Million
Previous $5.73 Million
139.95%
% of portfolio
0.05%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding XERS
# of Institutions
236Shares Held
94.1MCall Options Held
251KPut Options Held
61.8K-
Black Rock Inc. New York, NY10.3MShares$74.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.83MShares$71.3 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.84MShares$42.3 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA4.14MShares$30 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$27.1 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $986M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...